SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| Sohi Mohsen | Director | 2026-08-12 | Option exercise | 4058 | $350K |
| Sohi Mohsen | Director | 2026-08-12 | Open-market sell | 4058 | $957K |
| Sohi Mohsen | Director | 2026-07-01 | Option exercise | 3781 | $270K |
| Sohi Mohsen | Director | 2026-07-01 | Tax withholding | 1837 | $390K |
| Zangerle John Adam | Sr. VP, Gen Counsel, and Sec. | 2026-06-15 | Open-market sell 10b5-1 | 1419 | $297K |
| Carestio Daniel A | President and CEO, Director | 2026-06-05 | Open-market sell 10b5-1 | 1374 | $291K |
| Burton Karen L | Sr. Vice Pres., CFO | 2026-06-04 | Tax withholding | 90 | $19K |
| Carestio Daniel A | President and CEO, Director | 2026-06-04 | Tax withholding 10b5-1 | 1889 | $401K |
| Carestio Daniel A | President and CEO, Director | 2026-06-04 | Open-market sell 10b5-1 | 3054 | $656K |
| Fraser Mary Clare | SVP & Chief HRO | 2026-06-04 | Tax withholding | 600 | $127K |
| Kohler Kenneth E | SVP & GM, AST | 2026-06-04 | Tax withholding | 150 | $32K |
| Madsen Julia | Sr. VP and GM, Life Sciences | 2026-06-04 | Tax withholding | 195 | $41K |
| Tamaro Renato | V.P. & Corporate Treasurer | 2026-06-04 | Tax withholding | 65 | $14K |
| Zangerle John Adam | Sr. VP, Gen Counsel, and Sec. | 2026-06-04 | Tax withholding | 401 | $85K |
| Burton Karen L | Sr. Vice Pres., CFO | 2026-06-03 | Tax withholding | 190 | $40K |
| Carestio Daniel A | President and CEO, Director | 2026-06-03 | Tax withholding | 2619 | $550K |
| Fraser Mary Clare | SVP & Chief HRO | 2026-06-03 | Tax withholding | 311 | $65K |
| Kohler Kenneth E | SVP & GM, AST | 2026-06-03 | Tax withholding | 184 | $39K |
| Madsen Julia | Sr. VP and GM, Life Sciences | 2026-06-03 | Tax withholding | 239 | $50K |
| Tamaro Renato | V.P. & Corporate Treasurer | 2026-06-03 | Tax withholding | 64 | $13K |
Fiscal period ending 2026-03-31 versus 2025-03-31 — view filing on EDGAR →
Regulatory and tax risk has materially broadened, with new concrete exposures spanning IRS dual-taxation challenges, GloBE safe harbor ineligibility, OBBBA Medicaid funding cuts, and multi-jurisdictional carbon pricing — while the removal of Section 7874 risk is offset by a net increase in tax complexity. Competitive and strategic risks also escalated, with new customer insourcing threats in the AST segment and expanded M&A/JV/divestiture obligations adding operational complexity. The one meaningful easing (Section 7874 removal) is more than counterbalanced by the breadth of new and escalated exposures across regulatory, tax, competitive, and strategic themes.
8 company-specific · 1 eased/removed · 4 common-mode
New specific legislative risk disclosed: OBBBA may reduce Medicaid funding and reimbursements, directly threatening customer purchasing power and revenue.
Healthcare Policy and Reimbursement Changes in healthcare policy or government and other third-party payor reimbursement levels to healthcare providers, or failure to meet healthcare reimbursement or…
New disclosure of IRS challenge risk: potential dual U.S.-Ireland taxation and withholding tax on dividends to non-U.S. shareholders materially escalates tax exposure.
Changes in tax treaties and trade agreements could negatively impact our costs, results of operations and earnings per share. Legislative and regulatory action may be taken in the U.S. which, if…
Settlement expanded to include October 2025 agreement; claims process ongoing with court approval pending and potential for further litigation if settlement terms unfulfilled.
Our EO sterilization operations subject us to claims of liability and associated adverse effects . Some current or past operators of EO sterilization facilities, including us, have been the target of…
Added specific USMCA review risk (July 2026) and state/non-state actor language. Escalates trade policy uncertainty from general to concrete near-term event with potential tariff/qualification changes.
The effects of geopolitical instability may adversely affect us and create significant risks and uncertainties for our business, with the ultimate impact dependent on future developments, which are…
Added specific risks: tax examination challenges, withholding taxes on cross-border transfers, and potential material changes to tax provisions. Escalates from general uncertainty to concrete operational tax risks.
Tax Risks We may be adversely impacted by changes in tax laws or challenges to our tax positions, and our effective tax rate is uncertain and may vary from expectations, which could have a material…
New tax legislation (OBBBA) introduced; GloBE safe harbor clarification reveals company ineligible despite U.S. presence, increasing tax exposure risk.
Current economic and political conditions make tax rules in any jurisdiction subject to significant change. The One Big Beautiful Bill Act (the “OBBBA”) was signed into law on July 4, 2025. Some…
New disclosure of customer insourcing risk in AST segment and explicit need for continued capital investment to maintain competitive position materially escalates competitive threat.
BUSINESS AND OPERATIONAL RISKS Our business environment is highly competitive, and if we fail to compete successfully, our revenues and results of operations may be negatively impacted . We operate…
Expanded scope to include joint ventures and dispositions; new disclosure of post-divestiture financial obligations and contingent liabilities from divested businesses.
STERIS has incurred and expects to incur significant transaction and related costs in connection with strategic transactions, which may be in excess of those anticipated. STERIS has incurred…
Removal of Section 7874 tax risk eliminates material dual-taxation exposure and withholding tax liability that could have materially harmed financial condition.
The U.S. Internal Revenue Service (the “IRS”) may not agree that we are a non-U.S. corporation for U.S. federal tax purposes. Although we are organized under the laws of Ireland and are a tax…
Language shifted from "cannot assure" to "may not protect," and added explicit consequence language about financial impact, escalating the stated risk.
Compliance with multiple, and potentially conflicting, international laws and regulations, import and export limitations, anti-corruption laws, and exchange controls may be difficult, burdensome or…
Added specific regulatory conflict risk: EU sustainability requirements vs. U.S. restrictions on ESG practices. Escalates from generic stakeholder disagreement to concrete jurisdictional compliance tension.
Expectations relating to corporate responsibility considerations expose us to potential liabilities, increased costs, reputational harm and other adverse effects on our business. Many governments…
Risk escalated: added "expanded carbon pricing mechanisms" as new cost driver, emphasized "enhanced costs," and expanded scope to multiple jurisdictions (UK, California) with inconsistent regimes requiring costly compliance management.
We may be adversely affected by global climate change or by existing and future legal, regulatory or market responses to such change. The long-term effects of climate change are difficult to assess…
Added joint venture risk alongside M&A integration. Expands scope of strategic risks and operational complexity beyond acquisitions alone.
The integration of acquired businesses into STERIS or working arrangements with joint venture partners may not be as successful as anticipated. The integration of acquired businesses into STERIS as…
This is a classic Item 5.07 disclosure of shareholder voting results from STERIS plc's 2026 Annual General Meeting held July 31, 2026. The filing reports final voting tallies on seven matters: election of nine board directors, ratification of Ernst & Young LLP as independent auditor, appointment of Ernst & Young Chartered Accountants as statutory auditor, auditor compensation authorization, non-binding say-on-pay vote, renewal of board authority to issue shares, and renewal of pre-emption rights opt-out. All proposals passed with substantial majorities. This is material as it reflects shareholder governance decisions and board composition changes.
View raw filing on EDGAR →STERIS issued a press release on August 5, 2026 announcing financial results for fiscal 2027 first quarter ended June 30, 2026, with revenue growth of 7% to $1.5 billion, diluted EPS of $2.04 (adjusted EPS of $2.59), and segment-level performance metrics across Healthcare, AST, and Life Sciences divisions.
View raw filing on EDGAR →STERIS announced a targeted consolidation plan involving closure of chemistry manufacturing and distribution facilities in St. Louis, Missouri, and Plymouth, Minnesota, with anticipated restructuring charges of $55–70 million ($40–50 million cash, $15–20 million non-cash) and completion by fiscal 2030.
View raw filing on EDGAR →